Yoshimatsu Yuki, Kragholm Kristian, Clemmensen Silas Zacharias, Melgaard Dorte, Torp-Pedersen Christian, Smithard David G, Riis Johannes
Geriatric Medicine, Queen Elizabeth Hospital, Lewisham and Greenwich NHS Trust, London, UK.
Centre for Exercise Activity and Rehabilitation, School of Human Sciences, University of Greenwich, London, UK.
Age Ageing. 2024 Feb 1;53(2). doi: 10.1093/ageing/afae012.
Older adults are susceptible to anticholinergic effects. Dysphagia and pneumonia are associated with anticholinergic usage, though a definitive causative relationship has not been established. There is no effective way to predict the prognosis of older adults with pneumonia; therefore, this study investigates the predictive value of anticholinergic burden.
Patients aged 65 years and above admitted for community-acquired pneumonia from 2011 to 2018 in Denmark were included through Danish registries. We calculated anticholinergic drug exposure using the CRIDECO Anticholinergic Load Scale (CALS). The primary outcome was in-hospital mortality, and other outcomes included intensive care unit admission, ventilator usage, length of stay, 30-day/90-day/1-year mortality, institutionalisation, home care utilisation and readmission.
186,735 patients were included in the in-hospital outcome analyses, 165,181 in the readmission analysis, 150,791 in the institutionalisation analysis, and 95,197 and 73,461 patients in the home care analysis at follow-up. Higher CALS score was associated with higher in-hospital mortality, with a mean risk increasing from 9.9% (CALS 0) to 16.4% (CALS >10), though the risk plateaued above a CALS score of 8. A higher CALS score was also associated with greater mortality after discharge, more home health care, more institutionalizations and higher readmission rates.
High anticholinergic burden levels were associated with poor patient outcomes including short-/long-term mortality, dependence and readmission. It may be useful to calculate the CALS score on admission of older patients with pneumonia to predict their prognosis. This also highlights the importance of avoiding the use of drugs with a high anticholinergic burden in older patients.
老年人易受抗胆碱能效应影响。吞咽困难和肺炎与抗胆碱能药物的使用有关,尽管尚未确立明确的因果关系。目前尚无有效的方法来预测老年肺炎患者的预后;因此,本研究调查了抗胆碱能负担的预测价值。
通过丹麦登记处纳入了2011年至2018年在丹麦因社区获得性肺炎入院的65岁及以上患者。我们使用CRIDECO抗胆碱能负荷量表(CALS)计算抗胆碱能药物暴露量。主要结局是住院死亡率,其他结局包括重症监护病房入住、呼吸机使用、住院时间、30天/90天/1年死亡率、机构化、家庭护理利用和再入院。
186,735名患者纳入住院结局分析,165,181名纳入再入院分析,150,791名纳入机构化分析,随访时95,197名和73,461名患者纳入家庭护理分析。较高的CALS评分与较高的住院死亡率相关,平均风险从9.9%(CALS 0)增加到16.4%(CALS>10),尽管风险在CALS评分高于8时趋于平稳。较高的CALS评分还与出院后更高的死亡率、更多的家庭医疗护理、更多的机构化和更高的再入院率相关。
高抗胆碱能负担水平与包括短期/长期死亡率、依赖性和再入院在内的不良患者结局相关。在老年肺炎患者入院时计算CALS评分以预测其预后可能是有用的。这也凸显了避免在老年患者中使用抗胆碱能负担高的药物的重要性。